Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QXQ | ISIN: FI4000115464 | Ticker-Symbol: N/A
Lang & Schwarz
08.11.24
21:31 Uhr
14,250 Euro
-14,250
-100,00 %
1-Jahres-Chart
DETECTION TECHNOLOGY OYJ Chart 1 Jahr
5-Tage-Chart
DETECTION TECHNOLOGY OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
14,20014,30021:31
GlobeNewswire (Europe)
17 Leser
Artikel bewerten:
(0)

Detection Technology Oyj: Detection Technology Plc half-yearly report January-June 2024

Finanznachrichten News

Detection Technology Plc company announcement 6 August 2024 at 09:00 (EEST)

DETECTION TECHNOLOGY PLC HALF-YEARLY REPORT JANUARY-JUNE 2024

Detection Technology Q2 2024: Strong result, record industrial sales

April-June 2024 highlights

  • Net sales increased by 3.5% to EUR 26.1 million (25.2)
  • Net sales of Industrial Solutions Business Unit (IBU) increased by 42.6% to EUR 5.3 million (3.7)
  • Net sales of Medical Business Unit (MBU) decreased by -25.3% to EUR 9.3 million (12.4)
  • Net sales of Security Business Unit (SBU) increased by 26.7% to EUR 11.5 million (9.1)
  • Operating profit (EBITA) was EUR 3.3 million (1.4)
  • Operating margin (EBITA-%) was 12.7% of net sales (5.4%)

January-June 2024 highlights

  • Net sales increased by 1.7% to EUR 48.8 million (48.0)
  • Net sales of IBU increased by 24.8% to EUR 8.9 million (7.2)
  • Net sales of MBU decreased by -23.1% to EUR 18.8 million (24.5)
  • Net sales of SBU increased by 28.8% to EUR 21.1 million (16.3)
  • Operating profit (EBITA) was EUR 5.6 million (2.8)
  • Operating margin (EBITA-%) was 11.4% of net sales (5.9%)

UNAUDITED (Figures in parentheses refer to the corresponding period of the previous year.)


President and CEO, Hannu Martola:

"Our Q2 result strengthened both year-on-year and when compared to Q1. Our total net sales were slightly better than expected, thanks to strong sales in security and record sales in industrial applications. Sales in the medical market were weak as expected, but market signals are encouraging.

The positive trend in the industrial market continued and our industrial application sales soared, which resulted into record quarterly sales. Better-than-expected demand in TFT (thin-film transistor) flat panel detectors in Asia and growth in our legacy business were the underlying factors of this positive turn. Demand improved in all main applications, including the applications for the food industry. We expect growth to continue in Q3, too.

Demand in the medical market was particularly poor, and our sales remained modest, as anticipated. Sales were negatively affected by the same factors as in Q1, including, in particular, the measures by the Chinese government to reform its healthcare sector and the related anticorruption campaign targeted at healthcare end operators. However, it was delightful to see some positive signals from the market indicating the easing of the anti-corruption campaign towards the end of the year. Our order book and sales prospects have improved, and we, therefore, expect medical sales to increase from Q3 onwards.

Robust growth in our security application sales continued. Sales in computed tomography (CT) applications for the aviation industry in the Western market were strong, but demand was also good for line scanner applications. Our view on the accelerated growth in the global security market strengthened. We have an advantageous position to meet increasing demand in particular in the CT segment, and we expect our security application sales to continue growing.

Our Q2 result improved both year-on-year and when compared to Q1. Improved productivity, sales mix, and growth in sales from Q1 were the cornerstones of our good result. Good results and strong cashflow allowed the early repayment of the long-term loan used for the acquisition of Haobo Imaging. We are confident that we will be close to our medium-term operating margin target of 15 percent this year.

We have made progress in the development of our Indian business and founded a subsidiary in the New Delhi area. Our goal is to build a local service and manufacturing unit for the growing Indian market. India is spending big on infrastructure, and we want to participate in these projects.

The first EU Origin products were delivered from our Oulu unit during the review period, and our modular production will allow us to flexibly increase our production capacity. This has enhanced customer experience and improved our competitiveness and risk mitigation. Nearly 10 percent of our products sold will be manufactured in Finland by the end of the year.

The factors that have negatively impacted business due to the healthcare reform in China and the related anti-corruption campaign are estimated to gradually ease towards the end of the year, and we expect our medical sales to grow in Q3. Robust growth will continue in our other main markets, and both our security and industrial application sales will experience double-digit growth in Q3. We expect our total net sales to have double-digit growth in Q3 and H2 of 2024."


Key figures

(EUR 1,000)4-6/20244-6/20231-6/20241-6/20231-12/2023
Net sales26,09325,21948,79947,972103,794
Change in net sales, %3.5%10.8%1.7%11.4%5.3%
EBITA excluding NRI3,3061,3515,5702,8279,656
EBITA excluding NRI, %12.7%5.4%11.4%5.9%9.3%
Non-recurring items (NRI)0000-873
EBITA3,3061,3515,5702,8278,784
EBITA, %12.7%5.4%11.4%5.9%8.5%
R&D costs3,0493,0795,5606,04111,702
R&D costs, % of net sales11.7%12.2%11.4%12.6%11.3%
Cash flow from operating activities3,9112,4266,8271,9419,672
Net interest-bearing debt at end of period-14,744-18,530-14,744-18,530-12,665
Investments3523761,48582814,426
Return on investment (ROI), %13.9%6.5%13.9%6.5%9.9%
Gearing, %-19.9%-27.2%-19.9%-27.2%-17.4%
Earnings per share, EUR0.150.030.260.090.38
Earnings per share (diluted), EUR0.150.030.260.090.38
Number of shares at the end of the period14,655,93014,655,93014,655,93014,655,93014,655,930
Weighted average number of shares outstanding14,655,93014,655,93014,655,93014,655,93014,655,930
Weighted average number of shares outstanding, diluted14,661,75414,662,20614,658,84214,665,89414,660,912


Business outlook

Detection Technology expects its total net sales to grow double-digit in Q3 and H2 of 2024.

Geopolitical situation, U.S.-China relations, global economy, the measures taken in China to reform its healthcare, price competition especially in China, the indirect impacts of the war in Ukraine, and events in the Middle East create uncertainty.

Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.


Q2 2024 webcast

Hannu Martola, the President and CEO of Detection Technology, will present the Q2 and January-June 2024 financial performance and events to analysts, investors, and media at a webcast. The live webcast in English will begin on 6 August 2024 at 13:00 (EEST).

A link to the webcast is available on the company's website at https://www.deetee.com/reports-and-presentations/webcasts/. A recording of the webcast will be accessible later on the same page.


This release is a summary of Detection Technology's half-yearly report January-June 2024. The complete report can be found attached to the release and on the company's website.


Board of Directors, Detection Technology Plc


Further information

President and CEO Hannu Martola will be available for interviews and further information on the release date at 9:00-11:00 (EEST).

Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com

Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774

Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.

Distribution: Nasdaq Helsinki, key media, www.deetee.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.